Use of ipilimumab in the treatment of melanoma

Utkarsh H Acharya, Joanne M Jeter Department of Medicine, Division of Hematology-Oncology, University of Arizona Cancer Center, Tucson, AZ, USA Abstract: Ipilimumab is a monoclonal antibody directed against cytotoxic T-lymphocyte antigen-4 that has been approved by the US Food and Drug Administratio...

Description complète

Enregistré dans:

Détails bibliographiques
Auteurs principaux:	Acharya UH, Jeter JM
Format:	article
Langue:	EN
Publié:	Dove Medical Press 2013
Sujets:	Therapeutics. Pharmacology RM1-950
Accès en ligne:	https://doaj.org/article/a70e26a273564598bfe74b138ede085e
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!

id	oai:doaj.org-article:a70e26a273564598bfe74b138ede085e
record_format	dspace
spelling	oai:doaj.org-article:a70e26a273564598bfe74b138ede085e2021-12-02T02:07:39ZUse of ipilimumab in the treatment of melanoma1179-1438https://doaj.org/article/a70e26a273564598bfe74b138ede085e2013-08-01T00:00:00Zhttp://www.dovepress.com/use-of-ipilimumab-in-the-treatment-of-melanoma-a13988https://doaj.org/toc/1179-1438Utkarsh H Acharya, Joanne M Jeter Department of Medicine, Division of Hematology-Oncology, University of Arizona Cancer Center, Tucson, AZ, USA Abstract: Ipilimumab is a monoclonal antibody directed against cytotoxic T-lymphocyte antigen-4 that has been approved by the US Food and Drug Administration for the treatment of metastatic melanoma. Phase III trials have demonstrated an overall survival benefit with its use when compared with standard treatments and other investigational therapies. However, the drug poses a notable challenge, given its propensity for toxicity, and requires close surveillance when administered in clinical practice. This review discusses the mechanism of action for ipilimumab, its preclinical data, and the clinical trials that led to its approval by the Food and Drug Administration in 2011. Keywords: melanoma, immunotherapy, ipilimumabAcharya UHJeter JMDove Medical PressarticleTherapeutics. PharmacologyRM1-950ENClinical Pharmacology: Advances and Applications, Vol 2013, Iss Supplement 1, Pp 21-27 (2013)
institution	DOAJ
collection	DOAJ
language	EN
topic	Therapeutics. Pharmacology RM1-950
spellingShingle	Therapeutics. Pharmacology RM1-950 Acharya UH Jeter JM Use of ipilimumab in the treatment of melanoma
description	Utkarsh H Acharya, Joanne M Jeter Department of Medicine, Division of Hematology-Oncology, University of Arizona Cancer Center, Tucson, AZ, USA Abstract: Ipilimumab is a monoclonal antibody directed against cytotoxic T-lymphocyte antigen-4 that has been approved by the US Food and Drug Administration for the treatment of metastatic melanoma. Phase III trials have demonstrated an overall survival benefit with its use when compared with standard treatments and other investigational therapies. However, the drug poses a notable challenge, given its propensity for toxicity, and requires close surveillance when administered in clinical practice. This review discusses the mechanism of action for ipilimumab, its preclinical data, and the clinical trials that led to its approval by the Food and Drug Administration in 2011. Keywords: melanoma, immunotherapy, ipilimumab
format	article
author	Acharya UH Jeter JM
author_facet	Acharya UH Jeter JM
author_sort	Acharya UH
title	Use of ipilimumab in the treatment of melanoma
title_short	Use of ipilimumab in the treatment of melanoma
title_full	Use of ipilimumab in the treatment of melanoma
title_fullStr	Use of ipilimumab in the treatment of melanoma
title_full_unstemmed	Use of ipilimumab in the treatment of melanoma
title_sort	use of ipilimumab in the treatment of melanoma
publisher	Dove Medical Press
publishDate	2013
url	https://doaj.org/article/a70e26a273564598bfe74b138ede085e
work_keys_str_mv	AT acharyauh useofipilimumabinthetreatmentofmelanoma AT jeterjm useofipilimumabinthetreatmentofmelanoma
_version_	1718402724405444608

Use of ipilimumab in the treatment of melanoma

Documents similaires